jftlvªh laö Mhö,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II [k.m 3 mi&[k.m (ii) PART II Section 3 Sub-section (ii) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 470] ubz fnyyh] eaxyokj] iqjojh 6] 2018@ek?k 17] 1939 No. 470] NEW DELHI, TUESDAY, FEBRUARY 6, 2018/MAGHA 17, 1939 jlk;u vksj mozjd ea=ky; ¼vkS k/k fohkkx½ (र य औषध म य नध रण धकरण) vkns k ubz fnyyh] 6 Qjojh] 2018 dk-vk- 544¼v½. Hkkjr ljdkj ds jlk;u vksj mozjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebz] 2013 vksj dk- vk- 701¼v½ rkjh[k 10 ekpz] 2016 ds lkfk ifbr vks"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds isjk 5] 11 vksj 15 }kjk iznrr 'kfdr;ksa dk iz;ksx djrs gq,] jk"vªh; vks"k/k ewy; fu/kkzj.k izkf/kdj.k ¼ftldks laf{kir :i esa,uihih, dgk tkrk gs½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnz"v [kqnjk ewy; dks mdr lkj.kh ds LraHk ¼3½] ¼4½] vksj ¼5½ eas rrlfkkuh izfof"v;ksa esa fofufnz"v izcyrk] bdkbz ¼;wfuV½ vksj fofuekzrk vksj foi.ku deifu;ksa ds uke lfgr LraHk ¼2½ esa dh rrlfkkuh izfof"v esa ls izr;sd dh] olrq,oa lsok dj] ;fn dksbz gs] dks NksM+dj vf/kdre [kqnjk ewy; ds :i esa fu;r djrh gsa lkj.kh Ø- lafofufezfr dk uke@czkam dk uke izcyrk bdkbz fofuekzrk vksj foi.ku daiuh [kqnjk ewy; ¼#-½ (1) (2) (3) (4) (5) (6) 1. isjkflvkeksy $ MkblkbDyksekbu xksyh izr;sd vfyfir xksyh esa% isjkflvkeksy vkbzih 500 fexzk-] MkblkbDyksekbu 1 xksyh esllz,del MªXl,aM 1.64 ¼islheksy Likl½ gkbmªksdyksjkbm vkbzih 20 fexzk- vkbzihlh, yscksjsvksfjt 2.,eksDlhlhfyu iksvsf k;e DykoqykusV xksyh ¼DYkoke QkWjV MhVh½ izr;sd vfyfir fmisjflcy xksyh esa%,eksdlhlhfyu VªhgkbMªsV vkbzih ds cjkj,eksdlhlhfyu 400 fexzk-] iksvsf k;e DykoqykusV fmyqfvm vkbzih ds cjkcj DykoqykusV,flM 57 fexzk- 1 xksyh esllz,ydse yscksjsvksfjt 16.35 719 GI/2018 (1)
2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II SEC. 3(ii)] 3. VsyfelkjVu$DyksjFkkyh MkWu xksyh ¼fVxkysV lh,p 40½ 4. flyfumhfiu $VsyfelkjVu xksyh ¼Vsyoklhy 80 fexzk-½ VsyfelkjVu vkbzih 40 fexzk-] DyksjFkkyhMkWu vkbzih 12-5 fexzk- flyfumhfiu 10 fexzk-] VsyfelkjVu vkbzih 80 fexzk- 5. esvksizksyksy bzvkj xksyh izr;sd fqye fyfir,dlvsafmm fjfyt xksyh esa% esvksizksyksy lqllhusv vkbzih 71-25 ds cjkcj esvksizksyksy VkVsZªV 75 fexzk- 6. isjkflvkeksy$dsfqu xksyh ¼islheksy,DVho½ 7. MksDlhlk;lyhu$ ysdvªhd,flm ckflyl dsilwy 8. MksDlhlk;lyhu$ ysdvªhd,flm ckflyl dsilwy 9. lhyuhmhikbu $ VsyfelkjVu xksyh 10. lhyuhmhikbu $ VsyfelkjVu xksyh isjkflvkeksy vkbzih 650 fexzk-] dsfqu,ugkbmªksl vkbzih 50 fexzk- izr;sd gkmz tsysvkbu dsilwy esa% MksDlhlk;lyhu gkbdysv ds cjkcj MksDlhlk;lyhu ¼iSysVl½ 100 fexzk-] ysdvªhd,flm ckflyl ¼buVsfjd fyfir isysvl½ 5 fcfy;u liksjsl izr;sd gkmz tsysvkbu dsilwy esa% MksDlhlk;lyhu gkbdysv ds cjkcj MksDlhlk;lyhu ¼iSysVl½ 100 fexzk-] ysdvªhd,flm ckflyl ¼buVsfjd fyfir isysvl½ 5 fcfy;u liksjsl lhyuhmhikbu 10 fexzk-] VsyfelkjVu vkbzih 40 fexzk- lhyuhmhikbu 10 fexzk-] VsyfelkjVu vkbzih 40 fexzk- 11. ysohvsjklsve xksyh ysohvsjklsve vkbzih 1000 fexzk-] 12. ysohvsjklsve xksyh izr;sd fqye fyfir izksyksaxm fjfyt xksyh esa% ysohvsjklsve vkbzih 1000 fexzk-] 13. QsuhysQjkbu $ DyksjQsuhjkekbu flji 14. lqekvªhivu $ uizksdlsu xksyh ¼ukDldkWe½ 15. lhyuhmhikbu $ VsyfelkjVu $ DyksjFkkyhMkWu xksyh 16. VsyfelkjVu $,eyksmhfiu $ DyksjksFkkyhMkQu xksyh 17. VsyfelkjVu $,eyksmhfiu $ DyksjksFkkyhMkQu xksyh ¼VhxkVsy,lh,p 40½ izr;sd 5 fe esa% QsuhysQjkbu gkbmªksdyksjkbm vkbzih 5 fexzk-] DyksjQsuhjkekbu ekysv vkbzih 2 fexzkizr;sd vfyfir fcys;jm xksyh esa% lekvªhivku lqllhusv vkbzih ds cjkcj lqekvªhivu 85 fexzk-] uizksdlsu lksfm;e ;w,lih 500 fexzkizr;sd fqye fyfir xksyh esa% lhyuhmhikbu 10 fexzk-] VsyfelkjVu vkbzih 40 fexzk-] DyksjFkkyhMkWu vkbzih 6-25 fexzkizr;sd fqye fyfir xksyh esa% VsyfelkjVu vkbzih 40 fexzk-],eyksmhfiu ckbzlysv vkbzih ds cjkcj,eyksmhihu 5 fexzk-] DyksjksFkkyhMkQu vkbzih 12-5 fexzkizr;sd fqye fyfir xksyh esa% VsyfelkjVu vkbzih 40 fexzk-],eyksmhfiu ckbzlysv vkbzih ds cjkcj,eyksmhihu 5 fexzk-] DyksjksFkkyhMkQu vkbzih 12-5 fexzk- 1 xksyh esllz lu QkekZ yscksjsvksfjt 1 xksyh esllz I;ksj,aM D;ksj gsyfkds;j izk- @esllz,fjlvks QkekZL;wfVdYl izk 1 xksyh esllz buvkl QkekZL;wfVdYl 7.64 10.54 8.39 1 xksyh esllz bidk yscksjsvksfjt 1.88 1 dsilwy esllz ekldksv gsyfk flfjt izk- @esllz tk;ml gsyfkds;j 1 dsilwy esllz csuusv QkekZL;wfVdYl 1 xksyh esllz lqvsc ykbq lkbal@esllz yqfiu 1 xksyh esllz,del MªXl,aM,fjLVks QkekZL;wfVdYl izk 1 xksyh esllz ekldksv gsyfk flfjt izk- @esllz tk;ml gsyfkds;j 1 xksyh esllz,del MªXl,aM,eD;wj QkekZL;wfVdYl 1 fe esllz,del MªXl,aM ykbzqlvkj QkekZ izk- 1 xksyh esllz lu QkekZ yscksjsvksfjt 1 xksyh esllz lkbuksdse esudkbam QkekZ 1 xksyh esllz,del MªXl,aM QekZL;wfVdYl @esllz,ccksv bafm;k 1 xksyh esllz lu QkekZ yscksjsvksfjt 5.56 5.56 7.11 7.11 23.37 23.37 0.75 30.82 9.79 8.75 8.75
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 18. VsyfelkjVu $,eyksmhfiu $ DyksjksFkkyhMkQu xksyh ¼VhxkVsy,lh,p 80½ VsyfelkjVu vkbzih 80 fexzk-],eyksmhfiu ckbzlysvr vkbzih ds cjkcj,eyksmhihu 5 fexzk-] DyksjksFkkyhMkQu vkbzih 12-5 fexzk- 19. g~;weu balqfyu batsd ku izr;sd fe esa% g~;weu balqfyu ¼30 izfr kr?kqyu khu balqfyu batsd ku vksj 70 izfr kr blksqsu balqfyu batsd ku ds :i esa½ ¼g~;weu balqfyu vkjmh,u, vkwfjftu½ vkbzih 100 vkbz;w esvkfølksy ¼izstjosfVo ds :i esa½ ;w,lih&0-16 izfr kr MCY;w@oh] Qsuksy ¼izstjosfVo ds :i esa½ vkbzih 0-065 izfr kr MCY;w@oh okvj QkWj batsd ku 20. g~;weu balqfyu batsd ku izr;sd fe esa% g~;weu balqfyu ¼50 izfr kr?kqyu khu balqfyu batsd ku vksj 50 izfr kr blksqsu balqfyu batsd ku ds :i esa½ ¼g~;weu balqfyu vkjmh,u, vkwfjftu½ vkbzih 100 vkbz;w esvkfølksy ¼izstjosfVo ds :i esa½ ;w,lih&0-16 izfr kr MCY;w@oh] Qsuksy ¼izstjosfVo ds :i esa½ vkbzih 0-065 izfr kr MCY;w@oh okvj QkWj batsd ku 21. g~;weu balqfyu batsd ku izr;sd fe esa% g~;weu balqfyu ¼g~;weu balqfyu vkjmh,u, vkwfjftu½ vkbzih 100 vkbz;w esvkfølksy ¼izstjosfVo ds :i esa½ ;w,lih&0-025 izfr kr MCY;w@oh] Qsuksy ¼izstjosfVo ds :i esa½ vkbzih 0-065 izfr kr MCY;w@oh okvj QkWj batsd ku 22. MksdsVkDlsy batsd ku ¼MksdsVkDlsy vkbzih 120 fexzk-@3 fe½ 23. blhvkyksizke $ Dyksuktsike xksyh ¼ltsVkyks Iyl 5½ 24. VsyfelkjVu $,EyksfMfiu xksyh ¼VsyfeMwd,,e½ 25. VsyfelkjVu $ gkbmªksdyksjksfkkbtkbm xksyh ¼VsyfeMwd,p 40½ izr;sd fe dkwu kuvªsv esa% MksdsVkDlsy ¼,ugkbMªkst½ 40 fexzk-] iksyhlkscszv 80 &556 fexzkbfkkuksy,ugkbmªkst 326 fexzk-$ lkbfvªd,flm eksuksgkbmªsv 2 fexzk- ¼QkWj ih,p,mtslesav½ okvj QkWj batsd ku blhvkyksizke vksdlkysv vkbzih ds cjkcj blhvkyksizke 5 fexzk-] Dyksuktsike vkbzih 0-5 fexzkizr;sd vfyfir xksyh esa% VsyfelkjVu vkbzih 40 fexzk-],eyksfmfiu ckbzlysv vkbzih ds cjkcj,eyksfmfiu 5 fexzkizr;sd vfyfir xksyh esa% VsyfelkjVu ;w,lih 40 fexzk-] gkbmªksdyksjksfkkbtkbm ;w,lih 12-5 fexzk- 1 xksyh esllz lu QkekZ yscksjsvksfjt 1 fe esllz,ets ck;ksqkekz izk@esllz dks, QkekZL;wfVdYl izk- 1 fe esllz,ets ck;ksqkekz izk@esllz dks, QkekZL;wfVdYl izk- 1 fe esllz,ets ck;ksqkekz izk@esllz dks, QkekZL;wfVdYl izk- izfr isd ¼120 fexzk-@3 fe esllz osul jsemkbt @ esllz dsfmyk gsyfkds;j 1 xksyh esllz,lsav QkekZ@eSllZ,CcksV gsyfkds;j 1 xksyh esllz esdykwml QkekZL;wfVdYl 1 xksyh esllz esdykwml QkekZL;wfVdYl 14.00 10280.34 3.83 4.30 4.15 26. jkslqoklvkfvu$,lizhu $ DyksfiMksxzsy dsilwy ¼jkstqdksj xksym 10½ 27. jkslqoklvkfvu$,lizhu $ DyksfiMksxzsy dsilwy ¼jkstqdksj xksym 20½ izr;sd gkmz tsysvkbu dsilwy esa% jkslqoklvkfvu dsfy k;e vkbzih ds cjkcj jkslqoklvkfvu 10 fexzk- ¼iSysVl esa½],lizhu vkbzih 75 fexzk- ¼xkLVªks&jsflLVsuV isysvl½] DyksfiMksxzsy ckbzlyqsv vkbzih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½ izr;sd gkmz tsysvkbu dsilwy esa% jkslqoklvkfvu dsfy k;e vkbzih ds cjkcj jkslqoklvkfvu 10 fexzk- ¼iSysVl esa½],lizhu vkbzih 75 fexzk- ¼xkLVªks&jsflLVsuV isysvl½] DyksfiMksxzsy ckbzlyqsv vkbzih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½ 1 dsilwy esllz lkbuksdse VkWjsaV QkekZL;wfVdYl 1 dsilwy esllz lkbuksdse VkWjsaV QkekZL;wfVdYl 9.97 18.00
4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II SEC. 3(ii)] 28.,eksDlhlhfyu $ DykoqykusV llisa ku 29. isjkflvkeksy $ esqsukfed s ¼iklhekWy,e,Q 125½ 30. bvksfjdksdlhc $ isjkflvkeksy xksyh ¼bVkseSDl ih½ izr;sd dkwch isd esa% ¼,½ ou cksry vkwq,esdlhlhfyu,am iksvsf k;e DykoqykuV vksjy llisa ku,y-ih- izr;sd 5 fefyvkwq fjdulfvvwm llisa ku esa%,eksdlhlhfyu VªgkbMªsV vkbzih ds cjkcj,eksdlhlhfyu 400 fexzk-] iksvsf k;e DykoqykusV fmyqfvm vkbz ds cjkcj Dykoqyfud,flM 57 fexzkizr;sd 5 fe esa% isjkflvkeksy vkbzih 125 fexzk-] esqsukfed,flm vkbzih 50 fexzk Q~ykoksjsM flji csl bvksfjdksdlhc vkbzih 60 fexzk-] isjkflvkeksy vkbzih 325 fexzk- 1 fe esllz Vw,aVh QLV lsapwjh QkekZL;wfVdYl izk- @esllz XysuekdZ QkekZL;wfVdYl 1 fe esllz f=:ifr esmhds;j @esllz vkbzihlh, yscksjsvksfjt izk- 1 xksyh esllz jsosuhksy gsyfkds;j ¼ih½ @esllz vkbzihlh, izk- 2.91 0.48 5.14 uksv % ¼d½ mi;qzdr nh xbz fofufnz"v QkWewZys'ku ds fofuekzrk vfkkzr tks ÞubZ Mªxß Mhihlhvks] 2013 ds isjkxzkq 2¼;w½ ds rgr mi;qzdr nh xbz lkj.kh ds LraHk ¼6½ esa fofufnz"v [kqnjk ewy; fu/kkzfjr djsaxsa ¼[k½ vxj fuekzrkvksa us mi;qzdr lkj.kh ds LraHk (6) esa of.kzr vf/kdre dher ij ljdkj dks oklro esa Hkqxrku fd;k gs ;k ;g ns; gs rks os olrq,oa lsok dj dks tksm+ ldrs gsaa ¼x½ vks"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds isjkxzkq 11 esa fn, x, izko/kkuksa ds rgr fuekzrkvksa dks mi;qzdr lkj.kh ds LraHk ¼6½ esa fofufnz"v [kqnjk ewy; ds vk/kkj ij vuqlwfpr fofufezfr;ksa ds isdksa ds fy, [kqnjk ewy; fu/kkzfjr djsaa fuekzrk vks"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds isjkxzkq 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls,d ewy; lwph,uihih, dks vkbzihmh,e,l ds ek/;e ls tkjh djsaa ¼?k½ vks"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izr;sd QqVdj fodzsrk vksj forjd fofuekzrk }kjk fn, x, :i esa,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gs fd mlls ijke kz ds bpnqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn` ; Hkkx ij dher lwph vksj iwjd lwph] ;fn dksbz gks] dks laiznf kzr djsxka ¼M-½ mi;qzdr xsj vf/kdre dher ¼[kqnjk ewy;½ dsoy mi;qzdr fuekzrk@foi.ku ds fy, ykxw gs tslk fd mugksaus vks"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewy; fu/kkzj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vksj ljdkj }kjk fu/kkzfjr lhkh ykxw os/kkfud vko';drkvksa dh iwfrz ds v/khu izklafxd fof/k;ksa@fu;eksa ds vurxzr tslk fd dsunzh;@jkt; ykblsflax vkwfkksfjvh ds l{ke izkf/kdkjh }kjk esu;wqsdpfjax ykblsal eatwjh ds rgr lacaf/kr fofufezr fuekzrk@foi.ku deifu;ka tks vuqikyu djrh gsa ¼p½ fofuekzrk ;k foi.ku deiuh] mijksdr fofufezfr;ksa vksj fofufnz"v 'krks± dk ikyu ugha djrh gsa rks os vko';d olrq, vf/kfu;e] 1955 ds lkfk ifbr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizhkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsa ¼N½ bl vkns'k esa mijksdr lkj.kh ds LraHk ¼2½ esa dh rrlfkkuh izfof"v esa fofufnz"v fofufezfr;ksa ds isdksa dh [kqnjk ewy; fu;r gksus ds ifj.kkelo#i] vkns'k tks fd bl vkns'k ls iwoz tkjh gq, gs] Lor% gh fujlr gks tk;saxsa [dka-la-@186@54/2018@,q@qk- la0 8¼54½@2018@Mhih@,uihih,&fMoh-&II] MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 6th February, 2018 cythr flag] lgk;d funs'kd S. O. 544(E). In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30 th May, 2013 and S. O. 701(E) dated 10 th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5 column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; Sl. No. Name of the Formulation / Brand Name TABLE Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Paracetamol + Dicyclomine Tablet (Pacimol Spas) Each Uncoated tablet contains: Paracetamol IP 500mg, Dicyclomine Hydrochloride IP 20 mg 1 Tablet M/s Akums Drugs and Pharmaceutical / M/s IPCA Laboratories 1.64 2. Amoxicilin Potasium Clavulanate Tablet (Clavam Forte DT) 3. Telmisartan + (Tigatel CH40) Each uncoated dispersible tablet containing: Amoxicilin Trihydrate IP eq. to Amoxicilin 400mg, Potasium Clavulanate diluted IP eq. To Clavulanic acid 57 mg Each film coated Tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 12.5mg 1 Tablet M/s Alkem Healthscience-A unit of Alkem Laboratories / M/s Alkem labortories 1 Tablet M/s Sun Pharma Laboratories Limited 16.35 7.64 4. Cilnidipine + Telmisartan tablet (Telvacil 80mg) Each Tablet contains: Cilnidipine 10mg, Telmisartan IP 80mg 5. Metoprolol ER Tablet Each film coated extended release Tablet contains: Metoprolol Succinate IP 71.25mg eq. to Metoprolol Tartrate 75mg. 6. Paracetamol + Caffeine Tablate (Pacimol Active) 7. Doxycyclilne + Lactic Acid Bacillus capsules 8. Doxycyclilne + Lactic Acid Bacillus capsules 9. Cilnidipine + Telmisartan Tablet 10. Cilnidipine + Telmisartan Tablet Each film coated Tablet contains: Paracetamol IP 650mg, Caffeine Anhydrous IP 50mg Each hard Gelatin capsule contains: Doxycycline Hyclate eq. to Doxycycline 100mg, Lactic Acid Bacillus 5 Billion Spores Each hard Gelatin capsule contains: Doxycycline Hyclate eq. to Doxycycline (Pellets) 100mg, Lactic Acid Bacillus (enteric coated Pellets) 5 Billion Spores Each filmcoated tablet contains: Cilnidipine 10mg, Telmisartan IP 40mg Each filmcoated tablet contains: Cilnidipine 10mg, Telmisartan IP 40mg 11. Levetiracetam Table Levetiracetam IP 1000mg 12. Levetiracetam Table Each film coated Prolonged release tablet contains: Levetiracetam IP 1000mg 1 Tablet M/Pure and Cure Healthcare Pvt. / M/s Aristo 1 Tablet M/s Intas Pharmaceuticals Limited 1 Tablet M/s Ipca Laboratories Limited 1 Capsule M/s Mascot Health Series Pvt. / M/s Zydus Healthcare Limited. 1 Capsule M/s Bennet Pharmaceuticals 1 Tablet M/s Safteb Life Science / M/s Lupin Limited 1 Tablet M/s Akums Drugs & Pharmaceuticals / M/s Aristo 1 Tablet M/s Mascot Health Series Pvt. / M/s Zydus Healthcare Limited 1 Tablet M/s Akums Drugs & Pharmaceuticals / M/s Emcure 10.54 8.39 1.88 5.56 5.56 7.11 7.11 23.37 23.37
6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II SEC. 3(ii)] 13. Phenylephrine + Chlorpheniramine Syrup 14. Sumatriptan + Naproxen Tablet (NAXCOM) 15. Cilnidipine + Telmisartan + 16. Telmisartan + Amlodipine + (Telpres Trio) 17. Telmisartan + Amlodipine + (Tigatel ACH 40) 18. Telmisartan + Amlodipine + (Tigatel ACH 80) Each 5 ml Contains: Phenylephrine Hydrochloride IP 5mg, Chlorpheniramine Maleate IP 2mg Each uncoated bilayer tablet contains: Sumatriptan Succinate IP eq. to Sumatriptan 85mg, Naproxen Sodium USP 500mg Cilnidipine 10mg, Telmisartan IP 40mg, Chlorthalidone IP 6.25mg Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg, Chlorthalidone IP 12.5mg Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg, Chlorthalidone IP 12.5mg Each uncoated tablet contains: Telmisartan IP 80mg, Amlodipine Besylate IP Eq. to Amlodipine 5mg & Chlorthalidone IP 12.5mg Pharmaceuticals Limited 1 ML M/s Akums Drugs & Pharmaceuticals / M/s Lifestar Pharma Pvt. 1 Tablet M/Sun Pharma Laboratories Limited. 1 Tablet M/s Synokem Pharmaceuticals / M/s Mankind Pharma Limited 1 Tablet M/s Akums Drugs & Pharmaceuticals / M/s Abbott India Limited 1 Tablet M/s Sun Pharma Laboratories Limited 1 Tablet M/Sun Pharma Laboratories 0.75 30.82 9.79 8.75 8.75 14.00 19. Human Insulin Injection 20. Human Insulin Injection 21. Human Insulin Injection Insulin Biophasic Isophane PH. Eur./ USP (30% as soluble Insulin Injection and 70% as ISophane Insulin Injection) Each Ml contains: r-human Insulin (Regular) 100 IU/vial, m-cresol USP-0.16% w/v, Phenol IP 0.065% w/v Insulin Biophasic Isophane PH. Eur./ USP (50% as soluble Insulin Injection and 50% as ISophane Insulin Injection) Each Ml contains: r-human Insulin (Regular) 100 IU/vial, m-cresol USP-0.16% w/v, Phenol IP 0.065% w/v Soluble Insulin Ph. Eur./USP Each ml contains: r-human Insulin (Regular) 100 IU/vial 1 ML M/s MJ Biopharma Pvt. / M/s Koye 1 ML M/s MJ Biopharma Pvt. / M/s Koye 1 ML M/s MJ Biopharma Pvt. / M/s Koye 22. Docretaxel Injection (Docretaxel IP 120mg/3ml) Each ml of concentrate contains: Docetaxel (as anhydrous) 40mg, Polysorbate 80 566mg, Ethanol Anhydrous 326mg, Citric Acid Monohydrate 2mg (for PH adjustment), water for injection Each Pack (120mg/3 ml) M/s Venus Remedies / M/s Cadila Healthcare 10280.34 23. Escitalopram + Clonazepam Tablet (Szetalo Plus 5) Escitalopram Oxalate IP eq. to Escitalopram 5mg, Clonazepam IP 0.5mg 1 Tablet M/s Accent Pharma / M/s Abbott Healthcare Limited. 3.83
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7 24. Telmisartan + Amlodipine Tablet (Telmiduce AM) Each uncoated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg 1 Tablet M/s Macleods Pharmaceuticals 4.30 25. Telmisartan + Hydrocholrothiazide Tablet (Telmiduce H 40) Each uncoated tablet contains: Telmisartan USP 40mg, Hydrocholrothiazide USP 12.50mg 1 Tablet M/s Macleods Pharmaceuticals 4.15 26. Rosuvastatin + Aspirin + Clopidogrel Capsule (Rozucor Gold 10) 27. Rosuvastatin + Aspirin + Clopidogrel Capsule (Rozucor Gold 20) 28. Amoxycillin + Clavulante Suspension 29. Paracetamol + Mafenamic Suspension (Pacimol MF 125) Each Hard Gelatine Capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastation 10mg (As pellets), Aspirin IP 75mg (As Gastro - resistant pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets) Each Hard Gelatine Capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastation 20mg (As pellets), Aspirin IP 75mg (As Gastro - resistant pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets) Each combipack contains: (a) One bottle of Amoxycillin & Potassium Clavunate Oral Suspension L.P. Each 5ml of reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg, Potassium Clavulante Diluted IP eq. to Clavulnic Acid 57mg Each 5ml contains: Paracetamol IP 125mg, Mafenamic acid IP 50mg Flavoured Syrup base 1 Capsule M/s Synokem Pharmaceuticals Limited / M/s Torrent Pharmaceuticals Limited 1 Capsule M/s Synokem Pharmaceuticals Limited / M/s Torrent Pharmaceuticals Limited 1 ML M/s Twenty First Century Pharmaceuticals Pvt. / M/s Glenmark Pharmaceuticals 1 ML M/s Tirupati Medicare Limited / M/s IPCA Laboratories Pvt. 9.97 18.00 2.91 0.48 30. Etoricoxib + Paracetamol Tablet (Etomax P) Etoricoxib IP 60mg, Paracetamol IP 325mg 1 Tablet M/s Ravenbhel Healthcare (P) Limited / M/s IPCA Laboratories Pvt. 5.14 Note: (a) The manufacturer of above mentioned formulations i.e. new drug under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the
8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II SEC. 3(ii)] premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/186/54/2018/F/F.No. 8(54)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.